首页> 外文OA文献 >The city of hope experience with novel transplant regimens that incorporate standard and escalated dose 90YTTRIUM ibritumomab tiuxetan (90Y-Zevalin®) radioimmunotherapy (RIT) for autologous stem cell transplantation (ASCT) in patients with B-cell non-Hodgkin’s lymphoma (NHL): targeted intensification without increased toxicity and elimination of total body irradiation (TBI)

【2h】

The city of hope experience with novel transplant regimens that incorporate standard and escalated dose 90YTTRIUM ibritumomab tiuxetan (90Y-Zevalin®) radioimmunotherapy (RIT) for autologous stem cell transplantation (ASCT) in patients with B-cell non-Hodgkin’s lymphoma (NHL): targeted intensification without increased toxicity and elimination of total body irradiation (TBI)

机译：充满希望的城市，拥有结合标准剂量和递增剂量的90YTTRIUM ibritumomab tiuxetan（90Y-Zevalin®）放射免疫疗法（RIT）进行B细胞非霍奇金淋巴瘤（NHL）患者自体干细胞移植（ASCT）的新型移植方案：有针对性的强化治疗，而不会增加毒性并消除全身辐射（TBI）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Nademanee A.; Fung H.; Molina A.; Krishnan A.; Rodriguez R.; Popplewell L.; Spielberger R.T.; O’Donnell M.; Snyder D.; Parker P.; Stein A.; Kogut N.; Falk P.; Sahebi F.; Zain J.; Saville W.; Raubitschek A.; Forman S.J.;
展开▼
作者单位

展开▼
年度 2004
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience [J] . Ciochetto Chiara, Botto Barbara, Passera Roberto, Annals of hematology . 2018,第9期

机译：Yttrium-90 ibritumomab Tiuxetan（Zevalin）随后是梁（Z-梁）调节方案和自体干细胞移植（ASCT）复发或难治性高风险B细胞非霍奇金淋巴瘤（NHL）：一种机构意大利经验
2. Phase I trial of (90)Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation. [J] . Vose JM, Bierman PJ, Loberiza-FR Jr, Leukemia and lymphoma . 2007,第4期

机译：大剂量化疗和自体干细胞移植后复发性B细胞非霍奇金淋巴瘤患者的（90）Y-ibritumomab tiuxetan I期试验。
3. A Phase II, Safety and Efficacy Study of Fixed Dose Radioimmunotherapy (Zevalin, yttrium-90 ibritumomab tiuxetan) for Patients with Incomplete Response to Chemotherapy Prior to Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma [J] . Gao Limin, Sprague Kellie A., Nikpoor Nayer, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2015,第2Suppla1期

机译：固定剂量放射免疫疗法（Zevalin，yttrium-90 ibritumomab tiuxetan）用于多发性骨髓瘤自体干细胞移植（ASCT）之前对化学疗法反应不完全的患者的II期安全性和有效性研究
4. Yttrium-90 Ibritumomab Tiuxetan Doses Calculated to Deliver up to 15 Gy to Critical Organs May Be Safely Combined With High-Dose BEAM and Autologous Transplantation in Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma [O] . Jane N. Winter, David J. Inwards, Stewart Spies, -1

机译：Yttrium-90 Ibritumomab Tiuxetan剂量经计算可向关键器官提供高达15 Gy的剂量可与高剂量BEAM和自体移植安全地联合用于复发性或难治性B细胞非霍奇金淋巴瘤
5. A Phase II, Safety and Efficacy Study of Fixed Dose Radioimmunotherapy (Zevalin, yttrium-90 ibritumomab tiuxetan) for Patients with Incomplete Response to Chemotherapy Prior to Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma [O] . Gao Limin, Sprague Kellie A., Nikpoor Nayer, 2015

机译：固定剂量放射免疫疗法（Zevalin，yttrium-90 ibritumomab tiuxetan）用于多发性骨髓瘤自体干细胞移植（ASCT）之前对化学疗法反应不完全的患者的II期安全性和有效性研究

著录项

相似文献

相关主题

期刊订阅